What is Bright Minds Biosciences Inc.'s (DRUG) StockRank?

MoatMap's StockRank for Bright Minds Biosciences Inc. (DRUG) is 25/100, with a Sell signal. This is a composite score combining Quality (41), Value (26), and Momentum (43) factor ranks across MoatMap's 20,000+ stock universe.

Does Bright Minds Biosciences Inc. have an economic moat?

Bright Minds Biosciences Inc. (DRUG) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Bright Minds Biosciences Inc. a buy, hold, or sell?

MoatMap's current signal for Bright Minds Biosciences Inc. (DRUG) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Bright Minds Biosciences Inc. in?

Bright Minds Biosciences Inc. (DRUG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DRUG

Sell

Bright Minds Biosciences Inc. · Healthcare · United States · $714M · Avg Vol: $13M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-13.6%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel serotonin receptor agonists for the treatment of neuropsychiatric disorders. The company's proprietary small molecule drug candidates aim to selectively target specific serotonin receptor subtypes to address conditions like epilepsy, depression, and pain. It operates as a clinical-stage biotech firm, distinguished by its precision psychiatry approach to developing improved therapies for challenging central nervous system conditions.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2027E	Fwd CAGR
Revenue	0	0	0	0	—	—	21.8M	—
EPS	-1.56	-0.55	-0.22	-1.28	—	-2.06	—	—
Shares	9.8M	9.8M	9.8M	7.6M	-22.2%	9.8M	—	—
Debt	0.1M	52.9K	85.6K	90.5K	-3.5%	47.3K	—	—
Equity	7.6M	4.7M	4.0M	59.0M	98.2%	—	—	—
Op CF	-9.8M	-5.1M	-1.3M	-6.3M	—	-17.8M	—	—
Inv CF	—	—	—	—	—	—	—	—
Fin CF	3.7M	1.6M	0.6M	61.6M	—	—	—	—

Loading 1Y...

PRICE (1Y)-2.4%

SMA 50SMA 200

$72.81

RSI (14)

36.5

52W High

$123.75

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-38.0%21.1

ROE

-13.6%34.7

GP/Assets

—N/A

Op. Margin

0.0%40.1

FCF/Assets

-22.2%20.2

Piotroski

560.6

Int. Cover

—N/A

D/E Ratio

0.00x95.2

Current Ratio

121.97x99.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

4.7x30.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

59%33.3

RS 6M

-26%35.9

SMA 50/200

0.95x48.0

EPS Rev 4W

+31.5%96.9

EPS Rev 12W

+32.6%95.4

EPS Improve

-186%2.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$714M

P/E (Forward)

-13.0x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DRUG are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DRUG	Bright Minds Biosciences Inc.(you)	$714M	25	Sell
STTK	Shattuck Labs, Inc.	$707M	24	Sell
AURA	Aura Biosciences, Inc.	$767M	26	Sell
VSTM	Verastem, Inc.	$654M	25	Sell
CBIO	Crescent Biopharma, Inc.	$659M	26	Sell
NVCT	Nuvectis Pharma, Inc.	$775M	27	Sell
FDMT	4D Molecular Therapeutics, Inc.	$810M	26	Sell
MPLT	MapLight Therapeutics, Inc.	$584M	26	Sell
ACHV	Achieve Life Sciences, Inc.	$834M	22	Sell
ACRS	Aclaris Therapeutics, Inc.	$885M	23	Sell

Peer medians: ROE -25.9% · P/E 29.5x · Gross margin 58.8%

Bright Minds Biosciences Inc. (DRUG): Stock Score Summary

Bright Minds Biosciences Inc. (DRUG) has a MoatMap StockRank of 25/100 based on Quality (41/100), Value (26/100), and Momentum (43/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$72.81
Market Cap	$714M
P/E (Forward)	-12.99
Price/Book	4.70
Return on Equity	-13.6%
Return on Invested Capital	-38.0%
Debt/Equity	0.00x
Operating Margin	0.0%
Free Cash Flow	$-14M

Bright Minds Biosciences Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Bright Minds Biosciences Inc.’s (DRUG) StockRank?: MoatMap’s StockRank for Bright Minds Biosciences Inc. (DRUG) is 25/100, with a Sell signal. It is a composite of Quality (41), Value (26), and Momentum (43) factor ranks across MoatMap’s 20,000+ stock universe.
Does Bright Minds Biosciences Inc. have an economic moat?: Bright Minds Biosciences Inc. (DRUG) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bright Minds Biosciences Inc. a buy, hold, or sell?: MoatMap’s current signal for Bright Minds Biosciences Inc. (DRUG) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Bright Minds Biosciences Inc. in?: Bright Minds Biosciences Inc. (DRUG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).